Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Lung Cancer

  Free Subscription


17.02.2020

1 Ann Surg Oncol
1 Ann Thorac Surg
1 Arch Bronconeumol
3 BMC Cancer
1 Cancer Chemother Pharmacol
2 Chest
3 Clin Cancer Res
2 Eur J Cardiothorac Surg
1 Eur Respir J
3 Int J Cancer
1 Int J Oncol
9 Int J Radiat Oncol Biol Phys
1 J Cancer Res Clin Oncol
1 J Natl Cancer Inst
2 J Thorac Cardiovasc Surg
1 J Thorac Oncol
2 Lancet Oncol
2 Lancet Respir Med
1 Lung Cancer
1 Nat Med
3 Oncogene
1 Oncologist
7 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. ASARE EA, Silva-Figueroa A, Hess KR, Busaidy N, et al
    Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center.
    Ann Surg Oncol. 2019;26:3593-3599.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  2. GAMBAZZI F
    Imaging and Interdisciplinary Board: Both Are Important in Surveillance of Non-Small Cell Lung Cancer Patients.
    Ann Thorac Surg. 2020 Feb 8. pii: S0003-4975(20)30179.
    PubMed     Text format    


    Arch Bronconeumol

  3. MUNOZ-LUCAS MA, Jareno-Esteban J, Gutierrez-Ortega C, Lopez-Guijarro P, et al
    Influence of Chronic Obstructive Pulmonary Disease on Volatile Organic Compounds in Patients with Non-small Cell Lung Cancer.
    Arch Bronconeumol. 2020 Feb 10. pii: S0300-2896(20)30006.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. ZHENG J, Ye X, Liu Y, Zhao Y, et al
    The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.
    BMC Cancer. 2020;20:106.
    PubMed     Text format     Abstract available

  5. LAWRENSON R, Lao C, Brown L, Moosa L, et al
    Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent?
    BMC Cancer. 2020;20:109.
    PubMed     Text format     Abstract available

  6. HATTORI Y, Kono Y, Itoh S, Inoue T, et al
    A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2020;20:115.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  7. KAWAMURA T, Imamura CK, Kenmotsu H, Taira T, et al
    Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
    Cancer Chemother Pharmacol. 2020 Feb 10. pii: 10.1007/s00280-020-04034.
    PubMed     Text format     Abstract available


    Chest

  8. IACCARINO JM, Wiener RS
    Diagnostic Evaluation After Lung Cancer Screening in Real-World Practice: More Questions Than Answers.
    Chest. 2020;157:247-248.
    PubMed     Text format    

  9. MONU J, Triplette M, Wood DE, Wolff EM, et al
    Evaluating Knowledge, Attitudes, and Beliefs about Lung Cancer Screening Using Crowdsourcing.
    Chest. 2020 Feb 6. pii: S0012-3692(20)30251-8. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. DAGOGO-JACK I, Awad MM, Shaw AT
    BRAF Mutation Class and Clinical Outcomes-Response.
    Clin Cancer Res. 2019;25:3189.
    PubMed     Text format    

  11. IVANOVA E, Kuraguchi M, Xu M, Portell A, et al
    Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1844.
    PubMed     Text format     Abstract available

  12. DANKNER M, Rose AAN
    BRAF Mutation Class and Clinical Outcomes-Letter.
    Clin Cancer Res. 2019;25:3188.
    PubMed     Text format    


    Eur J Cardiothorac Surg

  13. JONES GD, Caso R, No JS, Tan KS, et al
    Prognostic factors following complete resection of non-superior sulcus lung cancer invading the chest wall.
    Eur J Cardiothorac Surg. 2020 Feb 10. pii: 5732798. doi: 10.1093.
    PubMed     Text format     Abstract available

  14. REA F, Ieva F, Pastorino U, Apolone G, et al
    Number of lung resections performed and long-term mortality rates of patients after lung cancer surgery: evidence from an Italian investigation.
    Eur J Cardiothorac Surg. 2020 Feb 8. pii: 5731323. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur Respir J

  15. KAUCZOR HU, Baird AM, Blum TG, Bonomo L, et al
    ESR/ERS statement paper on lung cancer screening.
    Eur Respir J. 2020;55.
    PubMed     Text format     Abstract available


    Int J Cancer

  16. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Text format     Abstract available

  17. ZHANG L, Wang MJ, Wang W, Zhao JY, et al
    Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis.
    Int J Cancer. 2020;146:103-114.
    PubMed     Text format     Abstract available

  18. QI L, Zhang Q, Miao Y, Kang W, et al
    Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
    Int J Cancer. 2020;146:1421-1434.
    PubMed     Text format     Abstract available


    Int J Oncol

  19. BIE F, Wang G, Qu X, Wang Y, et al
    Loss of FGL1 induces epithelialmesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma.
    Int J Oncol. 2019;55:697-707.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. DUIJM M, van der Voort van Zyp NC, van de Vaart P, Oomen-de Hoop E, et al
    Predicting High-Grade Esophagus Toxicity After Treating Central Lung Tumors With Stereotactic Radiation Therapy Using a Normal Tissue Complication Probability Model.
    Int J Radiat Oncol Biol Phys. 2020;106:73-81.
    PubMed     Text format     Abstract available

  21. LI R, Shinde A, Novak J, Vapiwala N, et al
    Temporal Trends of Resident Experience in External Beam Radiation Therapy Cases: Analysis of ACGME Case Logs from 2007 to 2018.
    Int J Radiat Oncol Biol Phys. 2020;106:37-42.
    PubMed     Text format     Abstract available

  22. ONG WL, Foroudi F, Milne RL, Millar JL, et al
    Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia.
    Int J Radiat Oncol Biol Phys. 2020;106:61-66.
    PubMed     Text format     Abstract available

  23. TANG C, Lee WC, Reuben A, Chang L, et al
    Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:349-357.
    PubMed     Text format     Abstract available

  24. TRIFILETTI DM, Ballman KV, Brown PD, Anderson SK, et al
    Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3).
    Int J Radiat Oncol Biol Phys. 2020;106:255-260.
    PubMed     Text format     Abstract available

  25. VAN MARLEN P, Dahele M, Folkerts M, Abel E, et al
    Bringing FLASH to the Clinic: Treatment Planning Considerations for Ultrahigh Dose-Rate Proton Beams.
    Int J Radiat Oncol Biol Phys. 2020;106:621-629.
    PubMed     Text format     Abstract available

  26. HAGAN M, Kapoor R, Michalski J, Sandler H, et al
    VA-Radiation Oncology Quality Surveillance Program.
    Int J Radiat Oncol Biol Phys. 2020;106:639-647.
    PubMed     Text format     Abstract available

  27. CORNELL M, Kaderka R, Hild SJ, Ray XJ, et al
    Noninferiority Study of Automated Knowledge-Based Planning Versus Human-Driven Optimization Across Multiple Disease Sites.
    Int J Radiat Oncol Biol Phys. 2020;106:430-439.
    PubMed     Text format     Abstract available

  28. GREWAL AS, Min EJ, Long Q, Grewal SK, et al
    Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy.
    Int J Radiat Oncol Biol Phys. 2020;106:358-368.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  29. CASTELLO A, Toschi L, Rossi S, Mazziotti E, et al
    The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2020 Feb 11. pii: 10.1007/s00432-020-03150.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  30. HAN SS, Chow E, Ten Haaf K, Toumazis I, et al
    Disparities of national lung cancer screening guidelines in the U.S. population.
    J Natl Cancer Inst. 2020 Feb 10. pii: 5732655. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  31. WU J, Bai HX, Chan L, Su C, et al
    Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: A National Cancer Database study.
    J Thorac Cardiovasc Surg. 2019 Dec 26. pii: S0022-5223(19)41497.
    PubMed     Text format     Abstract available

  32. LIN J
    Commentary: Through the looking glass: Is the consolidation/tumor ratio more important than size for clinical T1N0 lung cancer with a dominant ground-glass opacity?
    J Thorac Cardiovasc Surg. 2020 Jan 11. pii: S0022-5223(20)30071.
    PubMed     Text format    


    J Thorac Oncol

  33. GAO S, Li N, Gao S, Xue Q, et al
    Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Feb 6. pii: S1556-0864(20)30057.
    PubMed     Text format     Abstract available


    Lancet Oncol

  34. GARASSINO MC, Gadgeel S, Esteban E, Felip E, et al
    Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-contro
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(19)30801.
    PubMed     Text format     Abstract available

  35. FUNG AS, Leighl NB
    Advancing the systemic therapy of lung cancer: quality or quantity?
    Lancet Oncol. 2020 Feb 6. pii: S1470-2045(20)30076.
    PubMed     Text format    


    Lancet Respir Med

  36. DAWSON Q
    NELSON trial: reduced lung-cancer mortality with volume CT screening.
    Lancet Respir Med. 2020 Feb 6. pii: S2213-2600(20)30059.
    PubMed     Text format    

  37. KIRBY T
    Young non-smoker diagnosed with lung cancer.
    Lancet Respir Med. 2020;8:141-142.
    PubMed     Text format    


    Lung Cancer

  38. FINKE I, Behrens G, Schwettmann L, Gerken M, et al
    Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration.
    Lung Cancer. 2020;142:1-8.
    PubMed     Text format     Abstract available


    Nat Med

  39. LAUGHNEY AM, Hu J, Campbell NR, Bakhoum SF, et al
    Regenerative lineages and immune-mediated pruning in lung cancer metastasis.
    Nat Med. 2020;26:259-269.
    PubMed     Text format     Abstract available


    Oncogene

  40. KIM SJ, Garcia-Recio S, Creighton CJ, Perou CM, et al
    Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression.
    Oncogene. 2019;38:5942-5958.
    PubMed     Text format     Abstract available

  41. JALLOW F, O'Leary KA, Rugowski DE, Guerrero JF, et al
    Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer.
    Oncogene. 2019 Aug 12. pii: 10.1038/s41388-019-0941.
    PubMed     Text format     Abstract available

  42. SALIAKOURA M, Reynoso-Moreno I, Pozzato C, Rossi Sebastiano M, et al
    The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer.
    Oncogene. 2020 Feb 7. pii: 10.1038/s41388-020-1196.
    PubMed     Text format     Abstract available


    Oncologist

  43. PATEL SP, Pakkala S, Pennell NA, Reckamp KL, et al
    Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.
    Oncologist. 2020 Feb 12. doi: 10.1634/theoncologist.2020-0034.
    PubMed     Text format     Abstract available


    PLoS One

  44. TUVDENDORJ A, Feenstra T, Tseveen B, Buskens E, et al
    Smoking-attributable burden of lung cancer in Mongolia a data synthesis study on differences between men and women.
    PLoS One. 2020;15:e0229090.
    PubMed     Text format     Abstract available

  45. MILIAN L, Mata M, Alcacer J, Oliver M, et al
    Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    PLoS One. 2020;15:e0228909.
    PubMed     Text format     Abstract available

  46. MAMBETSARIEV I, Wang Y, Chen C, Nadaf S, et al
    Precision medicine and actionable alterations in lung cancer: A single institution experience.
    PLoS One. 2020;15:e0228188.
    PubMed     Text format     Abstract available

  47. ABARIUTE L, Lard M, Hebisch E, Prinz CN, et al
    Uptake of nanowires by human lung adenocarcinoma cells.
    PLoS One. 2019;14:e0218122.
    PubMed     Text format     Abstract available

  48. RABIN-COURT A, Rodrigues MR, Zhang XM, Perry RJ, et al
    Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
    PLoS One. 2019;14:e0218126.
    PubMed     Text format     Abstract available

  49. TAKADA K, Shimokawa M, Tanaka K, Kohashi K, et al
    Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
    PLoS One. 2019;14:e0217991.
    PubMed     Text format     Abstract available

  50. PARK KR, Yun JS, Park MH, Jung YY, et al
    Loss of parkin reduces lung tumor development by blocking p21 degradation.
    PLoS One. 2019;14:e0217037.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  51. YOUNG RP, Scott RJ
    Inhaled nicotine and lung cancer: Potential role of the nicotinic acetylcholine receptor.
    Proc Natl Acad Sci U S A. 2020 Feb 11. pii: 1921567117.
    PubMed     Text format    

  52. LIANG G, Meng W, Huang X, Zhu W, et al
    miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2020 Feb 10. pii: 1917531117.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: